- Driven by all three therapeutic areas, total sales grew 22.6% at constant exchange rates[1] and 17.0% at reported exchange rates; excluding Somatuline®, portfolio growth accelerated to 27.5% at constant exchange rates
- Strong momentum in the R&D pipeline, with three Phase III trial data readouts expected in the second half of 2026
- Full-year 2026 guidance confirmed[2]
ParisApril 24, 2026 /PRNewswire/ — Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company focused on specialty care, today announced its sales results for the first quarter of 2026.
David Loew, Chief Executive Officer of Ipsen, stated: “Ipsen had a strong start to 2026, with robust revenue growth and continued R&D pipeline progress as we advance our strategic priorities across all business areas. I am very pleased with the growth in our rare liver disease business, driven by the performance of Iqirvo and Bylvay. Additionally, with three Phase III trial data readouts expected this year and the initiation of three new late-stage projects, Ipsen is well-positioned to drive sustainable growth and create significant value for patients.”
2026 Full-Year Guidance
Ipsen confirms its full-year 2026 financial guidance[3]:
- Total sales growth exceeding 13.0% at constant exchange rates, based on accelerated growth in the portfolio excluding Somatuline and the assumption of Somatuline sales growth driven by challenges in lanreotide generic production. Based on average exchange rates in March 2026, currency is expected to have an unfavorable impact of approximately 1% on total sales
- Core operating margin exceeding 35.0% of total sales
Upcoming Milestones in 2026
Ipsen expects to achieve several key milestones across its portfolio in 2026, including:
- Iqirvo® (ELSPIRE trial) – Data readout from the pivotal Phase III trial in primary biliary cholangitis
- Bylvay® (BOLD trial) – Data readout from the pivotal Phase III trial in biliary atresia
- Dysport® (BEOND trial) – Data readout from the pivotal Phase III trial in chronic and episodic migraine
- Corabotase (IPN10200, LANTIC trial) – Data readout from the Phase II trial in lateral canthal lines and forehead lines
Data from Phase 1 of the Phase II LANTIC trial for Corabotase (IPN10200) will be presented at the 2026 Music City SCALE (Symposium on Cosmetic Advances and Laser Education) in May.
R&D Pipeline Update
On January 30, 2026, Ipsen entered into a global collaboration and exclusive option-to-acquire agreement with Origami Therapeutics, expanding its preclinical R&D pipeline in rare neurodegenerative diseases. This collaboration focuses on a research-stage protein degrader program targeting a hereditary neurodegenerative disease. If Ipsen exercises its option following successful candidate nomination, the company will assume full responsibility for global development and commercialization, further strengthening its strategy in rare neuroscience and first-in-class innovation.
On March 9, 2026, Ipsen announced the voluntary withdrawal of Tazverik® (tazemetostat) across all indications and markets, effective immediately, based on safety data emerging from the ongoing SYMPHONY-1 Ib/III trial in follicular lymphoma.
On April 22, 2026, following a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), the European Commission (EC) granted Ipsen conditional marketing authorization for Ojemda® (tovorafenib) as a monotherapy for the treatment of pediatric patients aged 6 months and older with low-grade glioma (pLGG) harboring BRAF fusions or rearrangements, or BRAF V600 mutations, whose disease has progressed after at least one prior systemic therapy. This approval is based on pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses.
Notes
All financial data are in millions of euros (€m). Unless otherwise stated, the reported results cover the three months ending March 31, 2026 (first quarter of 2026), compared with the three months ending March 31, 2025 (first quarter of 2025).
About Ipsen
Ipsen is a global biopharmaceutical company dedicated to providing innovative medicines in three therapeutic areas: oncology, rare diseases, and neuroscience.
Our R&D pipeline is driven by internal and external innovation and supported by nearly 100 years of development experience, with global centers in the United States, France, and the United Kingdom. With teams in over 40 countries and partners worldwide, we are able to deliver medicines to patients in more than 100 countries.
Ipsen is listed on Euronext Paris (ticker: IPN) and trades in the United States through a sponsored Level I American Depositary Receipt (ADR) program (ticker: IPSEY). For more information, visit ipsen.com.
About Ipsen in China
Ipsen Group entered China in 1992, established its China headquarters in Shanghai in 2021, and in 2022, following the group’s business restructuring, divested its multi-health business to focus on specialty care. In the three major therapeutic areas (oncology, rare diseases, and neuroscience), Ipsen China continues to introduce innovative treatment solutions to meet the urgent therapeutic needs of Chinese patients.
Ipsen – Cautionary Note Regarding Forward-Looking Statements
The forward-looking statements, objectives, and expectations contained in this document are based on Ipsen’s management strategy, current views, and assumptions. These statements involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those described herein. All of the aforementioned risk factors could affect Ipsen’s ability to achieve its future financial targets, which are based on currently available information and the assumption of a relatively stable macroeconomic environment. Words such as “believes,” “expects,” “anticipates,” and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events (such as regulatory submissions and approvals). Furthermore, the objectives described in this document do not assume external growth or potential future mergers and acquisitions, which could cause these metrics to change. These objectives are based on data and assumptions that Ipsen considers reasonable and depend on future circumstances, not solely on historical data. Due to several risks and uncertainties, actual results may differ significantly from these metrics, such as promising drugs in early development or clinical stages that may ultimately fail to reach the market or achieve commercial goals due to regulatory or competitive reasons. Ipsen faces, or may face, competition from generics, which could lead to market share loss. Additionally, the R&D process involves multiple stages, each carrying a significant risk that Ipsen may fail to meet its goals or even be forced to terminate projects with substantial resource investments. Therefore, Ipsen cannot guarantee that positive preclinical results will be replicated in subsequent clinical trials, nor that clinical trial results will be sufficient to demonstrate the safety and efficacy of the drugs in question. There is no guarantee that products will receive regulatory approval or achieve commercial success in the market. If underlying assumptions prove incorrect, or if risks and uncertainties materialize, actual results may differ materially from forward-looking statements. Other risks and uncertainties that could affect the company’s operations include, but are not limited to: general industry conditions and competitive landscape, macroeconomic factors (including interest rate and exchange rate fluctuations), pharmaceutical regulatory policies and healthcare legislation impacts, global cost-containment trends, technological advances and new drug/patent acquisitions by competitors, inherent challenges in innovative drug R&D (including obtaining regulatory approvals), Ipsen’s ability to assess future markets, manufacturing delays or difficulties, international financial instability and sovereign risks, Ipsen’s reliance on patents and other protections for innovative drugs, and potential litigation (including patent and compliance lawsuits). Furthermore, Ipsen relies on third-party partners for the development and commercialization of some drugs, which may generate significant royalty income. However, misconduct by such parties could adversely affect Ipsen’s business and financial results. Ipsen cannot guarantee that its partners will fully perform their obligations, nor that it will realize expected benefits from collaboration agreements. If partners default, the company’s revenue may fall below expectations, negatively impacting its business, financial condition, or operating performance. Unless required by applicable law, Ipsen expressly disclaims any obligation to update or revise any forward-looking statements, objectives, or forecasts in this press release to reflect changes in underlying assumptions or conditions. Ipsen’s business is also subject to the risk factors described in its registration documents filed with the Autorité des Marchés Financiers. These risks and uncertainties are not exhaustive, and readers are advised to consult Ipsen’s latest Universal Registration Document available on ipsen.com. Website: ipsen.com
|
[1] When calculated at constant exchange rates (CER), the performance for the relevant period is recalculated using the exchange rates applied in the prior period, excluding any foreign exchange impact. |
|
[2] Total sales growth exceeding 13.0% at constant exchange rates, core operating margin exceeding 35.0% of total sales |
|
[3] Excluding any impact from potential late-stage (Phase III clinical development or later) business development transactions. |